Neovacs S.A. (EPA:ALNEV)

Market Cap	7.45K
Revenue (ttm)	433.94K
Net Income (ttm)	-32.91M
Shares Out	2.07M
EPS (ttm)	-188.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,828,115
Average Volume	18,744,476
Open	0.0042
Previous Close	0.0042
Day's Range	0.0036 - 0.0046
52-Week Range	0.0036 - 4,150.0000
Beta	-167.20
RSI	28.60
Earnings Date	Apr 30, 2025

About Neovacs

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company’s product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of lupus erythematosus; and Phase IIa clinical trial for the treatment of dermatomyositis; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatme...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 22
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALNEV

Financial Performance

In 2024, Neovacs's revenue was 433,937, a decrease of -18.65% compared to the previous year's 533,412. Losses were -32.91 million, 276.4% more than in 2023.